#United States #Intensity Therapeutics #Shelton #INT230-6 #INVINCIBLE Study

Intensity Therapeutics Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology firm, has revealed plans for a public offering of its common stock. This strategic move is aimed at bolstering its financial resources to continue the development of unique intratumoral cancer therapies and facilitate patient enrollment in pivotal clinical trials. The Company specializes in innovative immune-based treatments that directly target tumors, aiming to not only destroy them but also enhance the immune system’s ability to recognize cancerous cells.

Purpose of the Offering

The primary goal of this stock offering is to generate sufficient proceeds to support ongoing and future clinical trials, particularly the INVINCIBLE-3 and INVINCIBLE-4 studies. The INVINCIBLE-3 study is investigating the efficacy of their investigational drug, INT230-6, for patients suffering from soft tissue sarcoma, aiming to test its safety and effectiveness against conventional treatment methods. The INVINCIBLE-4 study focuses on presurgical treatment of triple-negative breast cancer.

The funding will also be allocated to cover working capital and general corporate expenses, ensuring the ongoing operations of the Company are supported while they advance their research efforts. As the healthcare sector becomes increasingly competitive, having adequate funding will be critical to the success of Intensity Therapeutics in bringing their novel therapies to market.

Details of the Offering

The shares will be sold under a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). This registration process facilitates a quicker and streamlined approach to capital raising. The initial offering details will be laid out in a written prospectus that is made available to potential investors. ThinkEquity is serving as the sole book-running manager for this offering, consolidating their role in managing this significant raise.

For potential investors, the importance of reviewing the preliminary prospectus before making any investment is emphasized. Documents filed with the SEC, including the final details of the offering, will provide comprehensive insights into the Company’s objectives, operations, and financial health.

About Intensity Therapeutics

Founded to pioneer cancer treatment, Intensity Therapeutics has developed a groundbreaking approach whereby their drug formulations can effectively saturate a tumor’s unique environment after direct injection. This method has demonstrated significant results in early clinical trials, providing hope that conditions previously deemed intractable could be transformed into manageable, chronic issues. Their lead compound, INT230-6, has shown potential in rapidly eliciting an immune response against tumors, marking a turning point in cancer therapy.

To date, Intensity has successfully enrolled over 200 patients in previous studies, showcasing their commitment to rigorous clinical exploration. They have completed the Phase 1/2 dose escalation for metastatic cancers and launched further phases to comprehensively evaluate the safety and efficacy of INT230-6.

Conclusion

The decision by Intensity Therapeutics to pursue a public offering underscores its commitment to advancing innovative therapeutic options for cancer patients. By leveraging the proceeds from this offering, Intensity intends to enhance its research capabilities, push forward with critical trials, and ultimately contribute to evolving the landscape of cancer treatment. For ongoing updates and detailed insights into their clinical endeavors, interested parties are encouraged to visit the Company’s official website at www.intensitytherapeutics.com.

Investors and stakeholders should approach this offering with cautious optimism and remain informed about the potential impact of this new capital on the Company's ability to deliver transformative therapies to the oncology market.